Inventor · disambiguated record
Bruce Ewenstein
Also filed as: EWENSTEIN BRUCE
8 granted patents·8 pending applications·17 citations·filing 2012–2025
83Inventor score
Top patents by PatentIndex Score
16 records- 0191US12016904B2Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWFTAKEDA PHARMACEUTICALS CO·Filed 2022·Granted Jun 25, 2024·2 cites·22 claims
- 0289US11529395B2Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWFTAKEDA PHARMACEUTICALS CO·Filed 2020·Granted Dec 20, 2022·2 cites·20 claims
- 0387US10632176B2Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWFBAXALTA INC·Filed 2018·Granted Apr 28, 2020·3 cites·19 claims
- 0486US10905746B2Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWFBAXALTA INC·Filed 2020·Granted Feb 2, 2021·2 cites·36 claims
- 0580US2024316160A1Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwfTAKEDA PHARMACEUTICALS CO·Filed 2024·Application pending·0 cites
- 0678US9272021B2Treatment of coagulation disease by administration of recombinant VWFSCHEIFLINGER FRIEDRICH·Filed 2012·Granted Mar 1, 2016·6 cites·32 claims
- 0773US12128090B2Methods of prophylactic treatment using recombinant VWF (rVWF)TAKEDA PHARMACEUTICALS CO·Filed 2020·Granted Oct 29, 2024·1 cites·23 claims
- 0873US2024009279A1Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwfTAKEDA PHARMACEUTICALS CO·Filed 2023·Application pending·0 cites
- 0968US11191818B2Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndromeTAKEDA PHARMACEUTICALS CO·Filed 2017·Granted Dec 7, 2021·1 cites·45 claims
- 1066US2022168397A1Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwfTAKEDA PHARMACEUTICALS CO·Filed 2021·Application pending·0 cites
- 1165US2025387455A1Treatment of coagulation disease by administration of recombinant vwfTAKEDA PHARMACEUTICALS CO·Filed 2025·Application pending·0 cites
- 1263US12156903B2Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndromeTAKEDA PHARMACEUTICALS CO·Filed 2021·Granted Dec 3, 2024·0 cites·19 claims
- 1361US2019091298A1Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwfBAXALTA INC·Filed 2018·Application pending·0 cites
- 1449US2023201319A1Adamts13 compositions and methods for treating and diagnosing complications of coronavirus diseaseTAKEDA PHARMACEUTICALS CO·Filed 2021·Application pending·0 cites
- 1545US2022395560A1METHODS OF PROPHYLACTIC TREATMENT USING RECOMBINANT VWF (rVWF)TAKEDA PHARMACEUTICALS CO·Filed 2021·Application pending·0 cites
- 1643US2016184403A1Treatment of coagulation disease by administration of recombinant vwfBAXALTA INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Bruce Ewenstein files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →